Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) – Can They be Better than ADCs?

Medicinal Chemistry and Chemical Biology Highlights

Authors

  • Karl-Heinz Altmann ETH Zurich, Department of Chemistry and Applied Biosciences, HCI H405, Vladimir-Prelog-Weg 4, CH-8093 Zurich, Switzerland. karl-heinz.altmann@pharma.ethz.ch

DOI:

https://doi.org/10.2533/chimia.2018.154

Keywords:

Antibody-drug conjugates, Anticancer drug discovery, Small molecule-drug conjugates, Tumor targeting, Tumor uptake
CHIMIA Vol. 72 No. 03(2018): Quality Aspects in Industrial Chemistry

Downloads

Published

2018-03-30

Issue

Vol. 72 No. 3 (2018): Quality Aspects in Industrial Chemistry

Section

Columns, Conference Reports

Categories

License

Copyright (c) 2018 Swiss Chemical Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

[1]
K.-H. Altmann, Chimia 2018, 72, 154, DOI: 10.2533/chimia.2018.154.